Table 5.
Agents used in the treatment of COVID-19 patients.
| Agent | Number of studies | n/N | % | |
|---|---|---|---|---|
| Antiviral drug | Lopinavir | 4 | 4 | 4/54 (7.4) |
| Ritonavir | 4 | 4 | 4/54 (7.4) | |
| Oseltamivir | 1 | 1 | 1/54 (1.8) | |
| Remdesivir | 2 | 2 | 2/54 (3.7) | |
| Dihydrocodeine | 1 | 1 | 1/54 (1.8) | |
| Antibacterial drug | Azithromycin | 6 | 6 | 6/54 (11.1) |
| Cefpodoxime | 1 | 1 | 1/54 (1.8) | |
| Ceftriaxon | 2 | 2 | 2/54 (3.7) | |
| Cefoperazone-sulbactam | 1 | 1 | 1/54 (1.8) | |
| Omeprazole | 2 | 2 | 2/54 (3.7) | |
| Amoxicillin–clavulanic acid | 1 | 1 | 1/54 (1.8) | |
| Levofloxacin | 1 | 1 | 1/54 (1.8) | |
| Piperacillin/tazobactam | 1 | 1 | 1/54 (1.8) | |
| Rabeprazole | 1 | 1 | 1/54 (1.8) | |
| Metoclopramide | 1 | 1 | 1/54 (1.8) | |
| Temozolomide | 1 | 1 | 1/54 (1.8) | |
| Others | Apremilast | 1 | 1 | 1/54 (1.8) |
| HCQ | 10 | 10 | 10/54 (18.5) | |
| Prednisone | 2 | 2 | 2/54 (3.7) | |
| Paracetamol | 4 | 5 | 5/54 (9.2) | |
| Benzonatate | 1 | 1 | 1/54 (1.8) | |
| Heparin | 1 | 1 | 1/54 (1.8) | |
| Combination therapy | Lopinavir, Ritonavir, HCQ, Oral prednisone | 1 | 1 | 1/54 (1.8) |
| Azithromycin, Benzonatate | 1 | 1 | 1/54 (1.8) | |
| Lopinavir, Ritonavir, HCQ, Azithromycin | 1 | 1 | 1/54 (1.8) | |
| Temozolomide, Prednisone, Apremilast, Lopinavir, Ritonavir, Ceftriaxon | 1 | 1 | 1/54 (1.8) | |
| Azithromycin, HCQ, Cefoperazone-Sulbactam, Omeprazole | 1 | 1 | 1/54 (1.8) | |
| Amoxicillin–Clavulanic acid, Heparin | 1 | 1 | 1/54 (1.8) | |
| HCQ, azithromycin | 2 | 2 | 2/54 (3.7) | |
| HCQ, azithromycin, Remdesivir | 1 | 1 | 1/54 (1.8) | |
| Levofloxacin, HCQ | 1 | 1 | 1/54 (1.8) | |
| HCQ, omeprazole, Piperacillin, Tazobactam, Remdesevir | 1 | 1 | 1/54 (1.8) | |
| Lopinavir, Ritonavir, HCQ, Ceftriaxone, Rabeprazole, Paracetamol, Metoclopramide, Dihydrocodeine | 1 | 1 | 1/54 (1.8) |
*n, number of patients under treatment; N, the total number of patients with COVID-19.